NCM · Biotechnology

Virax Biolabs Group Limited (VRAX) Stock

$1.87 -6.03% NCM: VRAX Healthcare

Valuation

MetricValue
Price$1.87
Market Cap$348989
P/E Ratio-0.10
P/B Ratio0.13
P/S Ratio31.92
EPS (TTM)$-0.24
52-Week High$21.75
52-Week Low$1.86
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-114.24%
ROA-88.44%
ROCE-117.61%
Gross Margin—
Operating Margin—
Net Margin0.00%
Debt/Equity0.05
Current Ratio5.00

Annual Financials (USD)

Metric20222023202420252026
Revenue$0$0$0$0$0
Operating Profit$-2.0M$-6.0M$-6.0M$-6.0M$-6.0M
Net Profit$-2.0M$-5.0M$-7.0M$-6.0M$-5.0M
EPS$-37.50$-128.25$-84.00$-48.75$-12.64
Op Margin—-66963.7%-4153.3%-97344.8%-51515.2%

Balance Sheet (USD)

Metric20222023202420252026
Total Assets$0$10.0M$5.0M$6.0M$8.0M
Total Liabilities$1.0M$1.0M$0$1.0M$1.0M
Cash$0$9.0M$4.0M$4.0M$6.0M
Borrowings$0$0$0$0$0

Latest News

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement PR Newswire · Jul 16, 2026 Virax Biolabs enters immune profiling product supply deal with Fosun Hospital Management · Jul 13, 2026 Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds PR Newswire · Jul 10, 2026 Top Midday Decliners MT Newswires · Jul 10, 2026 Top Premarket Decliners MT Newswires · Jul 10, 2026

Cash Flow (USD)

Metric20222023202420252026
Operating Cash Flow$-1.0M$-4.0M$-6.0M$-5.0M$-5.0M
Investing Cash Flow$0$-1.0M$-2.0M$-1.0M$-1.0M
Financing Cash Flow$0$0$2.0M$1.0M$4.0M
Net Cash Flow$0$9.0M$-6.0M$1.0M$2.0M
Free Cash Flow$-1.0M$-4.0M$-7.0M$-5.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.71
FCF Yield-1773.30%
Quick Ratio9.90
Interest Coverage-96.86
Return 1Y-84.14%
Return 3Y-96.54%
Return 5Y—

Ownership

Insiders Held2.62%
Institutions Held4.61%
Institutions Float Held4.74%
Institutional HolderSharesReport Date
Armistice Capital, LLC35,1522026-03-31
Jump Financial, LLC1,6292026-03-31
Farther Finance Advisors, Llc12026-03-31
Osaic Holdings Inc.12026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARTLArtelo Biosciences, Inc. $3.23 -4.15% -0.05 $1.25M 0.00%
ATXIAvenue Therapeutics, Inc. $0.26 -32.94% -0.49 $856691 0.00%
DRMADermata Therapeutics, Inc. $1.06 -0.93% -0.25 $4.26M 0.00%
ELABPMGC Holdings Inc. $3.07 -1.92% 0.00 $1.39M 0.00%
GTBPGT Biopharma, Inc. $6.16 +3.27% -0.06 $7.77M 0.00%

About Virax Biolabs Group Limited

Virax Biolabs Group Limited is led by CEO James Foster, publicly traded since 2022.

Virax Biolabs Group Limited (VRAX) stock trades at $1.87 with a market capitalization of $348989. The stock is valued at a price-to-earnings (P/E) ratio of -0.10, price-to-book of 0.13, price-to-sales of 31.92. Over the past 52 weeks the stock has ranged between $1.86 and $21.75, and currently trades 91.4% below its 52-week high.

On profitability, Virax Biolabs Group Limited generates a return on equity (ROE) of -114.24%, return on capital employed of -117.61%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1175.48 +0.50% JNJ Johnson & Johnson $260.70 +1.65% ABBV AbbVie Inc. $276.78 +1.60% MRK Merck & Company, Inc. Common Stock (new) $146.11 +2.62% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.44 +2.29% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $660.73 +1.34% AMGN Amgen Inc. $416.60 +2.25% GILD Gilead Sciences, Inc. $151.22 +2.80% ABT Abbott Laboratories $99.16 +0.68% NVO Novo Nordisk A/S $38.42 +0.62%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides